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Abstract
In this investigation we used statistical methods to select genes with expression proﬁles that partition classes and subclasses of
biological samples. Gene expression data corresponding to liver samples from rats treated for 24 h with an enzyme inducer (phe-
nobarbital) or a peroxisome proliferator (cloﬁbrate, gemﬁbrozil or Wyeth 14,643) were subjected to a modiﬁed Z-score test to
identify gene outliers and a binomial distribution to reduce the probability of detecting genes as diﬀerentially expressed by chance.
Hierarchical clustering of 238 statistically valid diﬀerentially expressed genes partitioned class-speciﬁc gene expression signatures
into groups that clustered samples exposed to the enzyme inducer or to peroxisome proliferators. Using analysis of variance
(ANOVA) and linear discriminant analysis methods we identiﬁed single genes as well as coupled gene expression proﬁles that
separated the phenobarbital from the peroxisome proliferator treated samples and discerned the ﬁbrate (gemﬁbrozil and cloﬁbrate)
subclass of peroxisome proliferators. A comparison of genes ranked by ANOVA with genes assessed as signiﬁcant by mixed linear
models analysis [J. Comput. Biol. 8 (2001) 625] or ranked by information gain revealed good congruence with the top 10 genes from
each statistical method in the contrast between phenobarbital and peroxisome proliferators expression proﬁles. We propose building
upon a classiﬁcation regimen comprised of analysis of replicate data, outlier diagnostics and gene selection procedures to utilize
cDNA microarray data to categorize subclasses of samples exposed to pharmacologic agents.
 2002 Elsevier Science (USA). All rights reserved.
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1. Introduction
Analysis of microarray gene expression data has been
performed using various statistical methods to separate
and predict the clinical state of biological samples [1–5].
The computational challenge of partitioning and pre-
dicting subclasses or multiclasses of cancer tissue types
with a high-classiﬁcation success rate when using gene
expression proﬁling has been attempted yet still remains
a formidable problem [6–8]. Current gene selection al-
gorithms are particularly useful for selecting a subset of
predictive genes but fall short of identifying informative
genes ranked highest for classifying biological samples
[26,27]. A novel mixed model statistical analysis ap-
proach has been developed for analysis of cDNA and
oligo-based microarrays to assess signiﬁcant gene ex-
pression changes irrespective of the magnitude of eﬀect
or the level of relative mRNA abundance [28,29]. Uti-
lization of domain expertise and improved methods of
informative gene selection for supervised classiﬁcation
procedures is indeed a pragmatic approach to unequiv-
ocally utilize microarray gene expression data for pre-
diction of biological samples.
The advent of toxicogenomics brings together parallel
analysis of gene expression data for discernment of
mechanisms of toxicant action and predictive toxicology
[9]. Recently, eﬀorts have been made to use microarray
gene expression proﬁling for prognosis of toxic endpoint
phenotypes, elucidation of mechanistic-based toxicity in
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drug safety studies and prediction of chemical com-
pound signatures [10,11,30,31,33]. A clear understand-
ing of chemical compound class- and subclass-speciﬁc
mechanisms of action with identiﬁcation of distinct,
signiﬁcant and statistically valid gene expression signa-
tures will provide improved computational evaluation of
pharmacological biomarkers and biological surrogate
models that better understand the roles of gene-envi-
ronment interactions in human heath and disease.
In this paper we demonstrate the usefulness of repli-
cate experimental and biological microarray analyses to
select signiﬁcant gene expression proﬁles from rat liver
specimens exposed to pharmacologic agents. We illus-
trate the advantage of combining a conﬁdence level
approach with outlier detection and binomial proba-
bility distribution modeling to identify altered genes that
are statistically valid following chemical exposure and
compare results with observations obtained from the
data analyzed with a mixed models statistical approach.
We utilize single gene analysis of variance (ANOVA)
and linear discriminant analysis methods to identify a
distinct set of genes with expression patterns that indi-
vidually or in pairs, clearly separate classes- and sub-
classes of biological samples according to the category
of the pharmacologic agent treatment. Finally, we show
good congruence between informative genes ranked by
single gene ANOVA and genes ordered by information
gain or ranked as signiﬁcant by mixed linear models.
2. Methods
2.1. Gene expression data analysis
2.1.1. Data collection
Microarray gene expression data was derived from
mRNA samples collected from three rats per dose group
exposed to a single oral dose of either phenobarbital,
cloﬁbrate, Wyeth 14,643 or gemﬁbrozil, as well as
pooled RNA collected from 9 control (untreated) rats. A
liver specimen was collected from each treated rat 24 h
later and mRNA extracted from the tissues. Each RNA
sample from a treated animal was compared with the
pooled control mRNA analyzed in triplicate on a cus-
tom 1700 rat cDNA microarray chip, Rat Chip v1.0
[30]. Diﬀerentially expressed genes on each chip were
detected using a previously described ratio distribution
method [12] and annotated according to UniGene build
No. 93. Brieﬂy, digitized pixel intensity images gener-
ated by dual laser scanning of cDNA microarray chips
hybridized with ﬂuorescently labeled (Cy3 and Cy5)
cDNA probes were analyzed with ArraySuite v1.3 ex-
tensions of IPLabs image processing software (Scana-
lytics, Fairfax, VA). Pixel intensity values corresponding
to each cDNA feature on the microarray chip from both
scanning channels were adjusted by subtracting the local
background surrounding each gene target. The ratio of
the pixel intensity values for each gene target was nor-
malized to all genes spotted on the chip in order to
balance the two scanning channels to a ratio of ap-
proximately 1.0. Diﬀerentially expressed genes were
identiﬁed using the Chen et al. [12] probability-based
distribution method to calculate a 95% conﬁdence in-
terval for the ratio data. Genes with a normalized ratio
intensity value outside of the conﬁdence interval were
considered signiﬁcantly altered by the chemical treat-
ment.
2.2. Pattern recognition analysis
2.2.1. Statistical validation of expression proﬁles
Expression proﬁles from the diﬀerentially expressed
genes were managed in the MicroArray Project System
(MAPS) relational database [13]. InMAPS, amodiﬁedZ-
score, Mi for each gene expression ratio value, x, was
calculated for j genes using the sample median, ~x, and
median of the absolute deviates about the median, MAD
[14]. For i ¼ 1; 2; . . . ; j, MAD ¼ medianifjxi  ~xjg. Since
EðMADÞ ¼ 0:6745r (standard deviation),
Mi ¼ 0:6745ðxi  ~xÞ
MAD
: ð1Þ
A binomial distribution [15] was used to determine the
probability of detecting genes altered by chance for a
given treatment. That is for k ¼ 0; 1; 2; . . . ; n
Pk out of n ¼ n!k!ðn kÞ! ðp
kÞðqnkÞ; ð2Þ
where p is the probability of success in any single trial, q
is 1 p and n is the number of trials. For example,
scoring genes as diﬀerentially expressed at the 95%
conﬁdence level ðp ¼ 0:05Þ 4 or more times ðkP 4Þ out
of 9 replicate experiments ðn ¼ 9Þ has a probability (P)
of 0.00064 of being detected by chance.
2.2.2. Hierarchical clustering
A two-dimensional gene expression data matrix with
genes as the attributes (rows) and sample treatments as
the objects (columns) was generated using the set of
238 genes that were diﬀerentially expressed with at least
one of the chemical treatments and had a low proba-
bility ðP < 0:01Þ of being randomly detected at the 95%
conﬁdence level [13]. No more than 4 genes out of the
238 altered genes were determined by the binomial
distribution to be detected as false positive. For each
biological sample, the ratio intensity values for the 238
diﬀerentially expressed genes were log2 transformed to
approximate normality and averaged across replicate
hybridizations. Two-dimensional hierarchical cluster
analysis was performed using software and methods as
described by Eisen et al. [16] with the following pro-
cedures to direct the agglomerative application. The
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Pearson correlation coeﬃcient [17] was used as a
measure to determine similarity between gene expres-
sion vectors. Prior to clustering, the gene expression
vectors were subjected to 100,000 iterations of a self-
organizing map (SOM) [18] to order the genes within
clusters resulting in a smooth transition of gene ex-
pression patterns between clusters. The agglomerative
clustering [19] was executed iteratively to merge similar
gene expression vectors by measuring the distance of a
gene expression vector or cluster to all other gene ex-
pression vectors or clusters and merges the two that are
most similar.
2.2.3. Relevance analysis
To rank the 238 statistically valid diﬀerentially ex-
pressed genes according to the amount of gene expres-
sion information each gene contains to separate the
expression proﬁles acquired from the biological samples
treated with each class of agent m, the expected infor-
mation based on the separation of samples SfS1; S2;
. . . ; Svg by gene A is determined from the expected in-
formation needed to classify a sample
Iðs1; s2; . . . ; smÞ ¼ 
Xm
i¼1
pi log2ðpiÞ; ð3Þ
where pi is the probability ðsi=sÞ of a sample ðsiÞ be-
longing to class Ci and the entropy of the gene given by
its weighted average
EðAÞ ¼
Xv
j¼1
s1j þ 	 	 	 þ smj
s
Iðs1j; . . . ; smjÞ; ð4Þ
where smj is the number of samples in class Ci of subset v.
The information gain from the partitioning of the clas-
ses on A is deﬁned by
GainðAÞ ¼ Iðs1; s2; . . . ; smÞ  EðAÞ ð5Þ
and is used to rank the genes.
2.3. Gene selection for class determination
2.3.1. Single-gene analysis of variance
Prior to analyzing the gene expression data with
single-gene analysis of variance (ANOVA) model, the
ratio intensity measurements of all the genes were
screened for the presence of outliers. An outlier was
deﬁned as a value lying more than three global standard
deviations based on within-treatment pooled deviations
from the mean of the pharmacological treatment class
mean. Outlier ratio intensity values were replaced by the
class mean. Inter-chip variability was reduced by aver-
aging measurements for each biological sample treated
with a particular pharmacologic agent. In addition, re-
sults were post-processed to remove genes unless a
minimum global standard deviation of 0.3 was observed
indicating some minimal measurable treatment eﬀect.
For a particular toxicant treatment, let l1; l2; . . . ; lk
represent the mean expression values for the k compet-
ing genes. If each gene is measured n times, such that Yij
represents the jth measurement for gene i, then under the
one-way ANOVA model Yij ¼ li þ eij, where the errors,
eij, are assumed to be independent and identically dis-
tributed normal random variables,
l^i ¼ Yi ¼
1
n
Xn
j¼1
Yij ð6Þ
is the estimator for li ði ¼ 1; 2; . . . kÞ.
2.3.2. Linear discriminant analysis
Gene expression ratio intensity measurements were
screened for the presence of outliers as described in the
single gene analysis method. The linear discriminant
function is based on a Gaussian distribution of the gene
expression ratios for each class, with a common co-
variance matrix in all classes [22]. Gene-pairs were
ranked by the likelihood, P ðDatajli;RÞ, calculated for
the gene expression measurements for the rats in the ith
treatment (Data) given each treatments mean gene ex-
pression (li), and the pooled covariance (R). Gene-pairs
showing strong, consistent linear separation between the
treatment eﬀects ranked the highest.
3. Results
3.1. Diﬀerential gene expression analysis
3.1.1. Gene expression proﬁle variability
A scatter plot of the 24 h phenobarbital treated
sample1 and control sample2 (S1/S2) ratio intensity
values and the product of the sample intensities
ðS1 
 S2Þ indicated a weak dependence of ratios on the
intensity values particularly toward the low end of the
scanning dynamic range (Fig. 1A). The upper and lower
bounds from the 95% conﬁdence interval for the ratio
distribution [12] ﬁt the distribution of the data at the
high end of the intensity scale but are not consistent with
the spread of the ratio values at low intensities.
Diﬀerentially expressed genes can be conﬁrmed by
comparing replicate measurements of microarrays and
performing subsequent biological assays to assess the
biological signiﬁcance of altered gene expression [20,21].
To control for experimental and biological variability,
replicate cDNA array hybridizations were performed in
triplicate on each of the mRNA samples from three
individual rats. The Pearson correlation between two
experimental hybridization replicates using the same
biological sample were greater than 0.8 (data not
shown). Correlation between all the log2 ratio intensity
values acquired from the analysis of two microarrays of
two independent rats treated with phenobarbital for 24 h
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resulted in a Pearson correlation equal to 0.6 (Fig.
1B). The biological variability seen among individual
rats illustrates the degree to which an overall associa-
tion can be made regarding gene expression changes
due to a chemical compound treatment across biological
samples.
3.1.2. Gene expression signature outlier detection
To track and tally individual genes that were consis-
tently altered by chemical exposure, experimental in-
formation and diﬀerentially expressed genes from the
peroxisome proliferator and phenobarbital treatments
were managed in the MicroArray Project System
(MAPS) relational database [13]. In MAPS, a binomial
distribution was used to model the occurrences of dif-
ferentially expressed genes to determine the probability
of detecting an altered gene by chance at a given conﬁ-
dence level [15]. The binomial distribution modeling
indicated that 238 signiﬁcantly changed genes across the
experimental replicate hybridizations had a low proba-
bility ðP < 0:01Þ of containing genes that were randomly
detected as diﬀerentially expressed in 2 or 3 out of 3
replicate analyses. A comparison of these altered genes
with one-way analysis of variance (ANOVA) demon-
strated that the assumptions of normality and equal
variance for the ratio intensity values were likely vio-
lated. A normal quantile plot of the residuals from the
ANOVA suggests that the distribution is heavy-tailed,
since the points on the plot are not linear at the highest
and lowest values (Fig. 2A). These results suggest the
presence of outliers in the data.
Fig. 2. Distribution of the residuals from a one-way analysis of
variance of the ratio intensity values. The diﬀerence of the group
mean subtracted from each observation was graphed on a normal
quantile plot with 95% conﬁdence intervals, a linear ﬁt and plotted
as a frequency distribution with a normal distribution curve ﬁt
(A) before and (B) after outlier removal. The box plot illustrates
the median of the data as a line across the middle of the box, and the
25th and 75th quantiles lines extend from the end of the box to
the outermost data point that falls within the interquartile range. The
diamond inside the box signiﬁes the sample mean and the 95%
conﬁdence intervals.
Fig. 1. Scatter plots depicting intensity and ratio values dependence
and illustrating the correlation between biological replicates. Samples
were derived from livers exposed to phenobarbital. Log base-2 pixel
intensity values from treated (S1) and control (S2) samples are utilized
to assess ratio (S1/S2) and product ðS1 
 S2Þ values. (A) The pair-
wise comparison of the log2 ratio and product values from all the genes
is displayed with horizontal dashed lines indicating the upper and
lower conﬁdence limits obtained from ratio distribution calculations at
the 95% conﬁdence level [12]. (B) The pairwise comparison of the log2
ratio values of the validated outliers from biological replicates Rat1
and Rat2 is displayed. Pearson correlation (r) is 0.6.
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To detect and distinguish experimental outliers from
biologically diﬀerentially expressed genes, a modiﬁed Z-
score using the median of the absolute deviates (MAD)
was computed on the ratio intensity values. As shown in
Table 1, the modiﬁed Z-score computation detected the
three ratio intensity values from one of the biological
replicates expressing the gene for Solute carrier 16
(monocarboxylic acid transporter), member 1 (GenBank
AA956058) as outliers following treatment with gemﬁ-
brozil for 24 h.Only a subset of the diﬀerentially expressed
genes with this treatment is shown. From the microarray
analysis it was evident that two of the biological samples
repressed the gene following treatment whereas the third
induced the expression.Excluding the outliers reduced the
mean log base-2 ratio intensity value of the gene for Solute
carrier 16 (monocarboxylic acid transporter), member 1
from 0.01 to a modiﬁed mean of )1.12 therefore this gene
was excluded from further analysis. ThemodiﬁedZ-score
outlier detection recognized two ratio intensity values for
the gene for protein phosphatase 5, catalytic subunit
(GenBank AA957215); however, excluding them had a
negligible eﬀect on the calculation of the modiﬁed mean
and therefore this gene was retained for further analysis.
Removal of the outlier genes resulted in a normal quantile
plot of ANOVA residual values demonstrating that the
normality condition was met (Fig. 2B). The plot was lin-
ear and all points fell within the 95% conﬁdence bands.
Filtering the outliers reduced the heteroscedascity among
genes, making the assumption of equal variance more
reasonable (data not shown).
3.1.3. Toxicant gene expression pattern correlation anal-
ysis
Phenobarbital, a barbiturate and enzyme inducer, has
a diﬀerent mode of action than the peroxisome prolif-
erators Wyeth 14,643, gemﬁbrozil and cloﬁbrate [30].
Pair-wise comparisons of the 238 altered genes following
treatment with these agents for 24 h clearly shows good
correlation ðr > 0:8Þ between ﬁbrates (gemﬁbrozil and
cloﬁbrate), some correlation ðr > 0:5Þ between peroxi-
some proliferators and little correlation ðr < 0:4Þ be-
tween the peroxisome proliferators and enzyme inducer
(phenobarbital) gene expression proﬁles (Table 2). The
results in Table 2 illustrate the ability of cDNA micro-
array analysis to detect similar gene expression patterns
between chemicals from a particular class of compounds
as well as discriminate expression proﬁles from mecha-
nistically diﬀerent agents.
3.1.4. Hierarchical cluster analysis of expression proﬁles
Two-dimensional hierarchical clustering was
performed on the average ratio values of the three
Table 1
MicroArray Project System modiﬁed Z-score outlier detection of diﬀerentially expressed genes from samples treated with gemﬁbrozil
GenBank
Accession
Nos.
Description Log2 cal.
ratios
Hyb ID Modiﬁed
Z-scores
Mean (log2
cal. ratio)
Modiﬁed
mean (log2
cal. ratio)
Median
(log2 cal.
ratio)
Standard
error (log2
cal. ratio)
AA956058 Solute carrier 16
(monocarboxylic acid
transporter), member 1
)1.29 65 0.76
)1.03 92 0.14
)0.92 93 0.14
)1.15 66 0.43 0.01 )1.12 )0.97 0.55
)1.22 94 0.59
1.99 67 7.15
1.74 96 6.56
1.93 97 7.00
AA957215 Protein phosphate 5,
catalytic subunit
2.46 65 0.10
2.42 92 0.00
2.54 93 0.29
1.10 66 3.26
1.46 94 2.38 2.11 2.35 2.42 0.19
1.62 95 1.99
2.14 67 0.71
2.70 96 0.67
2.54 97 0.28
AA964507 Inhibitor of DNA binding
2, dominant negative
helix–loop–helix protein
)1.40 65 0.92
)1.18 93 0.00
)1.03 66 0.67 )1.21 )1.21 )1.18 0.07
)0.97 94 0.93
)1.51 67 1.43
)1.22 96 0.14
)1.18 97 0.00
Note. Statistics were generated using log2 calibrated ratio values for genes detected as diﬀerentially expressed in Section 2. Hyb ID denotes the
identiﬁer used for the hybridized array.
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experimental replicate analyses for the 238 genes that
were deemed to be diﬀerentially expressed in a statistically
signiﬁcantmanner relative to the control sample in at least
one of the agents tested. Clusters of genes with similar
gene expression patterns that distinguished samples
treated with phenobarbital from samples exposed to
peroxisome proliferators were identiﬁed. As shown in
Fig. 3, the phenobarbital treated samples clustered to-
gether and the peroxisome proliferator treated samples
clustered amongst each other. The cloﬁbrate treated
samples possessed less similarity in gene expression than
samples treated with gemﬁbrozil or Wyeth 14,643. In
particular, the clustering clearly demonstrates that two of
the cloﬁbrate treated samples are more similar to each
other in gene expression compared to the third cloﬁbrate
treated sample.
Highly correlated nodes of genes with similar ex-
pression vectors were identiﬁed by cutting the vertical
axis of the dendrogram and selecting clusters of genes
with a high degree of similarity ðr > 0:8Þ. As illustrated
in Fig. 3, two nodes contained genes with expression
patterns that discriminated samples treated with phe-
nobarbital from peroxisome proliferator exposed sam-
ples. The node No. 1 expanded on the dendrogram had
genes that were induced in the sample following phe-
nobarbital treatment but repressed or not diﬀerentially
Table 2
Pairwise correlations of ratio intensity values of genes identiﬁed as
diﬀerentially expressed from a sample treated with phenobarbital or
one of the peroxisome proliferators
Agents Cloﬁbrate Wyeth Gemﬁbrozil Phenobarbital
Cloﬁbrate 1 — — —
Wyeth 0.57 1 — —
Gemﬁbrozil 0.83 0.59 1 —
Phenobarbital 0.29 0.24 0.38 1
Fig. 3. Two-way hierarchical cluster analysis of validated gene expression proﬁles. Ratio intensity values of genes detected as diﬀerentially expressed
with a low probability ðP < 0:01Þ of being randomly detected at the 95% conﬁdence level from each biological sample following 24 h treatments were
log2 transformed, averaged across replicate hybridizations and subjected to agglomerative hierarchical clustering as described in Section 2. The
resulting gene expression proﬁle matrix contains the genes as the rows and experimental treatments as the columns with red indicating up regulation,
green denoting down regulation, black signifying no change and gray specifying missing data. The branches of the vertical and horizontal dendr-
ograms represent the amount of similarity between clustered genes and samples, respectfully. Two nodes containing highly correlated genes
ðr > þ0:8Þ across experimental samples are expanded for display.
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expressed following peroxisome proliferator treatments.
Conversely, the node No. 2 expanded on the dendro-
gram contained genes that were repressed in the sample
following phenobarbital treatments but induced or not
altered in expression following persoxisome proliferator
exposure.
3.2. Gene selection using ANOVA and LDA
The simplest approach to identifying genes aﬀected
by treatment is the now-standard measurement of n-fold
change. However, when replicates are available, it is
possible to account for some of the biological variability
within a treatment and determine not only which genes
change under treatment, but also which genes are af-
fected most consistently, and are least variable. With a
single gene ANOVA model, it is possible to rank the
genes by this consistency of eﬀect by comparing ANO-
VA P-values calculated by the comparison to the stan-
dard F distribution.
To identify genes that separate phenobarbital treat-
ment from peroxisome proliferator treatments, gene
expression data from biological samples treated with
Wyeth 14,643, gemﬁbrozil and cloﬁbrate were pooled
together. Application of the single-gene ANOVA clearly
identiﬁed the gene for cytochrome P450, 2b19 (Gen-
Bank AA818412) to have the most consistent and dra-
matic expression diﬀerence between phenobarbital and
the peroxisome proliferators. Cytochrome P450, 2b19
was the top ranking gene with an ANOVA score of
3:4e07. Other genes showing strong separation included
tripeptidylpeptidase (GenBank AI111901) and organic
cation transporter (GenBank AA965127). ANOVA
modeling highlighted singleton genes that provided
reasonable two-class separation. As shown in Fig. 4A,
the gene for cytosolic phosphoprotein (p19) (GenBank
AA957519) separated the peroxisome proliferator group
from the phenobarbital treated samples primarily from
the repressed expression of the gene with the latter
treatment and induced expression with the chemical
treatments in the former group.
Since single-gene rankings, like ANOVA or correla-
tion measures, are unable to identify gene-pair rela-
tionships, linear discriminant analysis (LDA) was
applied to each pair of genes to identify potentially in-
teresting gene couplings. LDA modeling of the data
identiﬁed singleton genes that were aﬀected by the dif-
ferent treatments as well as gene-pairs. Many of the
singleton genes found were the same as those reported
by the other analysis techniques, but a number of gene-
pairs were completely novel. The genes for cytochrome
P450, 2b19 and zinc ﬁnger protein (kid-1) mRNA
(GenBank AA965012) ranked highest with a LDA
separation score of 151.9 where the score is proportional
to the negative log likelihood of the separation. Several
of the top ranking gene-pairs separating peroxisome
Fig. 4. Single gene analysis of variance (ANOVA) and linear discriminant analysis (LDA). Subsequent to screening all the ratio intensity values for
the presence of outliers (see Section 2), measurements from the peroxisome proliferators Wyeth 14,643, cloﬁbrate, and gemﬁbrozil were grouped
together or all treatments including phenobarbital were treated as separate classes. Classes of treatments are denoted by a triangle and are indicated
in the graph legend. Log2 ratio pixel intensity values for genes are plotted for the (A and C) single gene ANOVA and the (B and D) LDA. (A) and (B)
abscissa positions are randomly jittered to assist visualization so that markers do not sit on top one another in the ordinate direction.
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proliferator treatments from phenobarbital treatment
contained the gene for cytochrome P450, 2b19 (Table 3).
Furthermore, many of the gene-pairs detected were
combinations of single genes from the ANOVA mod-
eling that provided good separation individually (data
not shown). However, some gene-pairs were not intui-
tively obvious and would not have been selected based
on other analyses. Fig. 4B illustrates the broad parti-
tioning of the two classes when the gene for tripept-
idylpeptidase II mRNA was combined with the gene for
nucleoporin p54 mRNA (GenBank AI030305).
The ANOVA and LDA methods were successful in
separating subclasses of peroxisome proliferator agents
exposed to the biological samples. Interestingly, when
all toxicants were treated as separate classes, the AN-
OVA identiﬁed the GluR-K3 gene for the glutamate
receptor (GenBank AA957877) as a single gene sepa-
rating phenobarbital from the peroxisome proliferators
while simultaneously separating cloﬁbrate, gemﬁbrozil
and Wyeth 14,643 peroxisome proliferator treatments
(Fig. 4C). The LDA ranked the pair of genes for G
protein coupled receptor kinase 5 (GenBank AA956162)
and mRNA for fast nerve growth factor receptor
(NGFR) the highest with a score of 57.4 to distinctly
separate the samples exposed to the four compound
treatments (Fig. 4D). The top ﬁve gene-pairs that sep-
arated all toxic agents involved the best singleton gene
for G protein coupled receptor kinase 5 suggesting that
the single-gene eﬀect is most predominant for this sep-
aration.
3.3. Comparison of genes selected as informative
A novel mixed linear models method of identifying
statistically signiﬁcant genes that are diﬀerentially ex-
pressed has been developed by Wolﬁnger et al. [28]. This
method has its advantages for analysis of gene expres-
sion data since it incorporates a factor eﬀects model with
multivariate terms in order to minimize type I and type
II error rates when detecting diﬀerentially expressed
genes. The mixed linear models gene expression data
analysis method is essentially a two-step ANOVA pro-
cedure that: (1) ﬁts the gene expression data to a nor-
malization model to account for main eﬀect of
treatments, systematic eﬀects of arrays, an interaction
eﬀect of arrays and treatments and corrects for sto-
chastic error, and (2) use the residuals from the nor-
malization model for a gene model to estimate the gene
by array eﬀects and measure the signiﬁcance of the gene
by treatment eﬀects.
We compared the ranking of genes using the single
gene ANOVA approach with the order of genes assessed
as signiﬁcant by mixed models analysis or ranked ac-
cording to information gain to assess the degree of
congruence between the selection of top informative
genes in a contrast between the phenobarbital treated
samples and the peroxisome proliferator treated samples.
The scorecard of the comparison depicted in Table 4 il-
lustrates that the union of the top 10 ranked genes from
each analysis method comprises a gene set where 12 of
the 21 genes are ranked in the top 20 in each statistical
approach. Looking across analysis methods, 8 of the 21
genes are ordered in the top 20 in two of the three
ranking methods. Interestingly, genes representing mi-
tochondrial 3-2trans-enoyl-CoA isomerase, cytochome
p450, phenobarbital-inducible and G protein coupled
receptor kinase (GenBank AA997009, AA818412, and
AA956162, respectively) are genes ranked in the top 10 in
each analysis approach. Not surprisingly, the other mi-
tochondrial 3-2trans-enoyl-CoA isomerase gene on the
array (GenBank AA965078) and Rattus norvegicus
tripeptidylpeptidase II were top 10 ranked genes in two
of the three analysis methods. Cytochome p450, pheno-
barbital-inducible and G protein coupled receptor kinase
genes scored ﬁrst or second in either of the three analysis
methods whereas R. norvegicus phosphoprotein phos-
phatase (GenBank AA957215) ranked second and third
in the mixed models and relevance analysis approaches,
respectively. R. norvegicus mRNA for cytokeratin type I
(GenBank AA956106) and R. norvegicus mRNA for
fetuin (GenBank AA955349) ranked 7th and 8th, re-
spectively with the single gene ANOVA but fairly low
ðrank > 100Þ with the mixed models and relevance
analysis methods.
4. Discussion
Classiﬁcation of biological samples is of immense
importance in biomedical research to determine the
clinical pathology of disease states. Alterations in gene
expression that reﬂect mechanistic changes are indicators
of the biology within clinical samples. Understanding the
biological variability within the microarray experimental
Table 3
Linear discriminant analysis top ranking gene-pairs separating peroxisome proliferators from phenobarbital
Gene1 Gene2 LDA separation
Cytochrome P450, 2b19 Zinc ﬁnger protein (kid-1) 151.9
Tripeptidylpeptidase II Nucleoporin p54 70.9
Cytochrome P450, 2b19 A2b-adenosine receptor 68.6
Cytochrome P450, 2b19 Synuclein 1 62.8
Cytochrome P450, 2b19 p38 mitogen activated protein kinase 61.1
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process is key to uncover important considerations in the
survey of speciﬁc signature proﬁles. Procedures such as
ascertaining the probability of false positives and false
negatives, or defeating the statistical error in the process
of analyzing microarray data, are essential for applying
transcriptional proﬁling to classiﬁcation of biological
samples [23,32]. We have demonstrated the advantage of
applying the binomial probability distribution and
modiﬁed Z-score computation to replicate microarray
gene expression data to validate the determination of
diﬀerentially expressed genes. The modiﬁed Z-score test
was essential in our process of detecting outliers in ratio
intensity values since the median of the absolute deviate
about the median (MAD) of the data, used to compute
the modiﬁed Z-score, is an unbiased estimator that is
minimally eﬀected by outliers (Table 1). Employing the
binomial distribution model to the genes identiﬁed as
diﬀerentially expressed genes at the 95% conﬁdence level
across replicate microarray experiment, permits building
upon Bernoulli trials to essentially diminish the 5% error
of detecting a gene as altered in a single experiment. For
instance, tallying genes as diﬀerentially expressed 4 times
out of 9 replicate experiments has a probability of
0.00064 of detecting a single gene by chance using a 1700
feature array. Although the ratio distribution method
establishes conﬁdence levels to assess the meaningfulness
of altered gene expression [12], an approach that com-
bines the advantages of conﬁdence levels with the beneﬁts
of individual gene p-values to assess signiﬁcance of
expression will undoubtedly improve the predictive
power of microarray gene expression data. Wolﬁnger
et al. [28,29] have embarked on such approaches with the
use of statistical mixed linear models to assess gene sig-
niﬁcance in microarray gene expression data irrespective
of the magnitude of eﬀect or the level of relative mRNA
abundance. Comparison of the top genes from single
gene ANOVA with genes ranked by information gain or
by signiﬁcance in the mixed models approach reveals a
good amount of validity and reliability between analysis
methods in a phenobarbital vs peroxisome proliferator
contrast (Table 4). Clearly, varying but valid results are
inevitable as was exhibited in the ranking of top classiﬁers
detected by our single gene ANOVA and linear discri-
minant analysis (LDA) suggesting that more attention
and application to the statistical analysis of microarray
gene expression data is required to uncover a concor-
dance of statistically signiﬁcant gene expression signa-
tures to ultimately classify biological samples with a high
degree of conﬁdence.
Pattern recognition algorithms have been useful in
the discovery of discrete and complex associations of
multivariate data in high-dimensional space. The com-
putational mechanisms employed in the various classi-
ﬁcation methods have distinct diﬀerences and
characteristics in the discriminatory process. Clustering
utilizes measurements of similarity and distance to de-
termine the degree of resemblance between compared
data sets [16–20]. LDA and single gene ANOVA rely on
computing and permuting the arithmetic mean values of
data sets to select vectors that separate samples into one
Table 4
Comparison of diﬀerentially expressed genes selected and ranked as informative in the phenobarbital vs peroxisome proliferator contrast
Description GenBank
Acc. No.
Single-gene ANOVA Mixed models Relevance analysis
Rank Score Rank  log p Rank InfoGain
R. norvegicus G protein coupled receptor kinase AA956162 1 2.84E-07 4 29.69 1 1.116
Rat GluR-K3 gene for the glutamate receptor AA957877 2 8.88E-07 22 17.51 44 0.580
R. norvegicus peroxisomal multifunctional enzyme type II AA874974 3 5.99E-06 32 14.19 34 0.638
Rat mRNA for mitochondrial 3-2trans-enoyl-CoA isomerase AA965078 4 6.08E-06 12 21.17 10 0.811
Rat mRNA for mitochondrial 3-2trans-enoyl-CoA isomerase AA997009 5 6.08E-06 6 23.99 9 0.811
Rat cytochrome p450- phenobarbital-inducible AA818412 6 6.72E-06 1 40.18 2 1.048
R. norvegicus mRNA for cytokeratin type 1 (30 end) AA956106 7 8.93E-06 107 7.04 118 0.445
R. norvegicus mRNA for fetuin AA955349 8 9.29E-06 252 3.30 1677 <0.001
R. norvegicus tripeptidylpeptidase II mRNA AI111901 9 1.18E-05 3 34.50 15 0.771
R. norvegicus nucleoporin (Nup98) AA924744 10 1.21E-05 44 12.09 39 0.590
R. norvegicus phosphoprotein phosphatase AA957215 11 1.49E-05 2 36.72 3 0.959
R. norvegicus mRNA for ribosomal protein S24 AA997138 13 1.97E-05 10 22.39 36 0.636
Rat serine pyruvate aminotransferase AI029012 23 5.18E-05 19 19.37 6 0.872
R. norvegicus mRNA for carboxylesterase precursor AI070587 25 6.42E-05 47 11.60 7 0.857
Rat epoxide hydrolase mRNA AA900551 36 1.73E-04 5 25.09 14 0.780
R. norvegicus Sprague–Dawley Ah receptor AA859478 44 3.02E-04 9 22.93 148 0.418
Rat dopa decarboxylase (DDC) AI044610 56 5.15E-04 8 23.71 281 0.339
Rat 5-aminolevulinate synthase AA924489 94 1.48E-03 7 23.88 232 0.361
Rat liver glutathione S-transferase Ya subunit AA818339 157 5.79E-03 20 18.46 5 0.896
Rat mRNA for a-tubulin AA957078 187 7.81E-03 51 11.35 4 0.926
R. norvegicus b-1-2-N-acetylglucosaminyltransferase II (Gnt II) AA955301 288 2.09E-02 55 11.01 8 0.833
Note. )Log p is the negative log10 of the p-value from the gene mixed model hypothesis test. InfoGain is the information gain for the gene and
score is the one-way ANOVA score for the gene (see Section 2).
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of two or more mutually exclusive classes. We used
LDA, single gene ANOVA and hierarchical clustering
of gene expression data, from samples treated with
phenobarbital, a barbiturate and enzyme inducer, or one
of the peroxisome proliferators chemical compounds, to
select genes with highly correlated expression proﬁles
that separate the treatments of the samples with the two
classes of agents while simultaneously partitioning sub-
classes of peroxisome proliferators. There was concor-
dance between the discriminator genes from the diﬀerent
classiﬁcation approaches suggesting suﬃcient richness
of the microarray data, speciﬁcity of the discriminating
proﬁles and robustness of the computational algorithms
to discern gene expression diﬀerences in the two-class
separation problem. However, while the LDA method
selected unique gene-pairs that separated the individual
treatments as well as the ﬁbrate subclass from the per-
oxisome proliferators class of agents, hierarchical clus-
tering and the ANOVA model identiﬁed groups of
genes, for example GenBank Accession Nos. AA818412,
AA964948, AI070587, AA965078, AA997009, and
AI111901, as genes that can discriminate phenobarbital
from the peroxisome proliferators. The cytochrome
P450, 2b19 phenobarbital-inducible gene (GenBank
Accession No. AA818412) is a pivotal component of
phenobarbital metabolism [24] whereas the tripeptidyl-
peptidase II gene (GenBank Accession No. AI111901),
normalizes rates of intracellular protein breakdown re-
quired for normal cellular function and viability [25].
In this report we present a classiﬁcation process con-
taining sequential steps to use microarray gene expres-
sion data and pattern recognition techniques to classify
chemical treatments of biological samples. The simpliﬁed
model shown in Fig. 5 outlines the key computational
procedures followed for understanding the adverse con-
sequences of exposure to chemical agents. Our results
suggest that discrete genetic markers exist for reactions to
xenobiotics in biological systems. Additional studies are
necessary to ultimately associate gene expression altera-
tions with phenotypic changes and biological endpoints
and to discern those gene changes associated with the
toxicity of a xenobiotic from the inherent pharmacolog-
ical properties. Supplementary proﬁling and classiﬁca-
tion exercises will demand a more diverse and robust
database of gene expression proﬁles in addition to rig-
orous and enhanced heuristic computational algorithms
to eﬀectively unearth and fully comprehend the funda-
mental concepts pertaining to the intricate genomic cir-
cuitry regulating biological processes.
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